Bernard Escudier

Researcher Next ID · RN-002250

Researcher · Medicine

Villejuif, France

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Economics, Econometrics and Finance

Renal cell carcinoma treatment

Cancer Genomics and Diagnostics

Renal and related cancers

Cancer Immunotherapy and Biomarkers

Economic and Financial Impacts of Cancer

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1712126
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Science · 2017 · https://doi.org/10.1126/science.aan3706
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1510665
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)61039-9
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
New England Journal of Medicine · 2007 · https://doi.org/10.1056/nejmoa060655

No projects listed.